Global Nicotine Gum Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts
17 janv. 2023 05h13 HE
|
Research and Markets
Dublin, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The "Nicotine Gum Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Smoking Cessation and Nicotine De-Addiction Products Market Report 2022: Featuring British American Tobacco, Cipla, Dr. Reddy's Laboratories & More
12 janv. 2023 08h28 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "Smoking Cessation and Nicotine De-Addiction Products Market By Product, By Form, By Distribution Channel: Global Opportunity Analysis and Industry...
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
09 janv. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
21 déc. 2022 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global...
Smoking Cessation and Nicotine De-Addiction Products Global Market to Grow by 15% Annually Through 2030
01 déc. 2022 07h33 HE
|
Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Smoking Cessation and Nicotine De-Addiction Products Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players,...
Achieve Life Sciences Announces Private Placement of $18.9 Million
15 nov. 2022 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update
14 nov. 2022 16h05 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
08 nov. 2022 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
31 oct. 2022 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
27 sept. 2022 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global...